Abstract 116P
Background
Colorectal cancer (CRC) ranks as the second leading cause of mortality, following lung cancer, among cancer-related fatalities in High Income Asia Pacific (HIAP) nations. Despite this, there remains a lack of consistent and comparable data on the burden of CRC in these regions.
Methods
Utilizing tools from the Global Burden of Disease study, we examined CRC's prevalence, incidence, mortality, and disability-adjusted life years (DALYs) by age groups, sex, and years across four HIAP countries from 1990-2019. Moreover, we employed a regression framework model to project CRC-related deaths until 2040.
Results
The aggregate number of prevalent CRC cases surged from 450,169 (95%UI: 433,127-466,354) in 1990 to 1,178,847 (1,026,274-1,347,590) in 2019. During the same period, the death toll increased from 34,338 (32,598-35,179) to 76,929 (64,820-83,603). When considering the annual percentage change (APC), DALYs exhibited a 65% increase from 1990 to 2019. Notably, the age-standardized incidence rate (ASIR) demonstrated a 15% rise in APC, with the most pronounced increases occurring in South Korea (119%), Brunei Darussalam (21%), and Japan (13%). Conversely, Singapore exhibited a 7% decline in ASIR during the same timeframe. In terms of age-standardized mortality rate (ASMR), South Korea reported the highest APC (17%), while Singapore and Japan witnessed declines of 40% and 15%, respectively. The most significant APC in DALYs was noted in Brunei Darussalam (178%), trailed by South Korea (176%), Japan (89%), and Singapore (50%). In 2019, the age group of 85-89 experienced the highest CRC-related deaths, whereas the 75-79 age group exhibited the highest incidence. Meanwhile, the 70-74 age group showed the highest DALYs. Over the past three decades, males carried a greater burden compared to females. By 2040, a projected increase of 73,633 (52,895-102,526) CRC-related deaths is anticipated.
Conclusions
In 2019, CRC contributed to 13.88% of all cancer-related casualties in HIAP nations. The burden of CRC varied persistently among these countries. Nonetheless, it is evident that there is an urgent requirement for the implementation of more effective strategies to mitigate the burden posed by CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract